Pancreatic Cancer Research

Clinical trialPhase 2Unknown

Electroporation Potentiated Immunotherapy in Cancer

A Phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
26 May 2021
Listed end
December 2025
Enrollment
8 participants
Sites
1
Primary outcomes
Objective response rate (ORR) according to RECIST 1.1; Serious adverse reaction (SAR) rate according to CTCAE v5
Sponsor type
Academic / other
Results posted
No
Last update
9 March 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The study is investigating the efficacy and safety of combined irreversible electroporation (IRE) and checkpoint inhibition in metastatic pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

The aim of the study is to investigate whether checkpoint inhibition in conjunction with IRE of a single liver metastasis can elicit a systemic anticancer immune response in patients with pancreatic cancer. Adult patients, in WHO performance status 0-1, with liver metastatic pancreatic cancer, intolerant to or progressing on first or further lines of chemotherapy can enter the trial. Pembrolizumab infusion is given every six weeks for up to six months. IRE of a single liver metastasis is performed between the first and second pembrolizumab infusion. Response to the therapy is examined by CT (RECIST) on non-IRE-ablated lesions every 2 months. Assessments of changes in peripheral blood immune cell composition, tumor gene expression and tumor infiltrating lymphocytes is performed on serial biopsies and blood samples.